primary end point), ii) secondary end points in the study were lung function (FEV1, FVC, FEF25-75 and PEFR), symptoms (need for corticosteroid burst, short-acting bronchodilator use such as albuterol, ipratropium) and peripheral eosinophils. They have shown significant effect of statins on ACT, however secondary end points remained unaffected or got worse with statin therapy.
For major concerns the following points need to be addressed: 1. When important physiological parameters associated with asthma included as secondary end point remain unaffected by the statin therapy and still authors were able to show significant improvement in ACT. This discrepancy mandates inclusion in Discussion regarding the merits and weaknesses of the ACT score, and its utility as an index of clinical impact. 2. Most of the severe asthmatics on statin therapy were taking statins for some co-morbid cardiovascular or hyperlipidemic conditions, so could the improvement in ACT score be somehow related to improvement in these co-morbid conditions and may not be associated with any improvement in asthma symptoms? 3. In the result section authors have talked about the effect of statins on only obese severe asthmatics, which is only a subgroup of severe asthmatics, but they have not mentioned the effect of statins on overall severe asthmatics included in the study. 4. Study Cohort does not define obese severe asthmatics, the statistical model selection (backward selection procedure), where different variables associated with asthma has been taken into consideration, should be described in the main body of the paper.
Apart from these there are few minor comments 1. Page#13 line#31-33: "The lipophilic statins, which have the greatest lipid lowering potency" is incorrect as Rosuvastatin is the most potent statin, which is hydrophilic in nature. 2. In the supplement material for statistical model development statistical significance has been observed at a p value≤0.1 instead of conventional 0.05 is there any specific reason for this?
REVIEWER
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THE STUDY
1. The exclusion criteria included "COPD or emphysema … (Page 9, Line 44 to 50). Since the close relationship of asthma to the diseases above, did authors check the X-ray, CT-scan or some other test to make sure of the exclusion?
2. The group of statin-user had significantly higher prevalence of CAD and hyperlipidemia than the non-user group. As we all know, coronary artery disease itself might cause chest tightness; and some of the patients may present with cardiac insufficiency, which were very likely to suffer from dyspnea, making it quite difficult for differential diagnosis just according to the symptoms. Furthermore, there were much more patients with CAD/ hyperlipidemia in statin group. Could it be possible that the better Adjusted Mean ACT score in statin-user group is mainly due to the statins effect on the coronary artery disease instead of asthma? In particular the study found that obese patient with severe asthma receiving statin therapy had slightly higher ACT scores than non-exposed controls. The authors acknowledge the limitations of the study -small sample size; retrospective study design; possibility of confounding factor(s). Nevertheless the observation is of interest as it provides some indirect evidence that statins may improve asthma outcomes in obese patients with moderate to severe asthma and provides support for a large randomized controlled trial of statin treatment in this sub-group of asthma.
VERSION 1 -AUTHOR RESPONSE
We appreciate Professor Thomson"s perspective and comments. We are in full agreement with him.
No major concerns were raised in this review.
Reviewer: Andrew J Halayko, PhD Professor of Physiology and Internal Medicine University of Manitoba
In this study authors have tried to argue that statin therapy could be beneficial to patients with severe asthma. To prove this they have done a retrospective study, where they have included only severe asthmatics who were either on statins and standard asthma therapy or only on standard asthma therapy (control group). They have tried to evaluate if statins can improve i) Asthma Control Test (ACT; primary end point), ii) secondary end points in the study were lung function (FEV1, FVC, FEF25-75 and PEFR), symptoms (need for corticosteroid burst, short-acting bronchodilator use such as albuterol, ipratropium) and peripheral eosinophils. They have shown significant effect of statins on ACT, however secondary end points remained unaffected or got worse with statin therapy.
Professor Halayko"s comments are also greatly appreciated and well taken. We have taken careful efforts to respond to each of them here and in the revised manuscript.
For major concerns the following points need to be addressed: 1. When important physiological parameters associated with asthma included as secondary endpoint remain unaffected by the statin therapy and still authors were able to show significant improvement in ACT. This discrepancy mandates inclusion in Discussion regarding the merits and weaknesses of the ACT score, and its utility as an index of clinical impact.
We appreciate and concur with this comment. The ACT score is one of several indicators of asthma symptom control, as shown in Table 2 . The advantage of the ACT score is that it is a validated survey with clinical utility that has predictive value for future exacerbations in the next 12-months. This was referenced in the original version of the manuscript (Ref #24) where we attempted to address the clinical value of our finding in the Discussion under the heading Significance of the Primary Endpoint: The ACT Score: "As a single measure in the clinic, the ACT score contains significant predictive power for determining asthma risk. Schatz et al. reported that the minimally important difference (MID) for ACT is a decrease of 3 points which confers a 76% increased risk of SABA use and 33% increased exacerbations over 12 months24. However, even a reduction of 2 points in the ACT score in their study indicates a 46% increased risk of SABA use and 21% increased exacerbations24."
Yet, we agree with Professor Halayko and appreciate his viewpoint. Therefore, we have addressed this important discrepancy in the Discussion by adding the following paragraph: "It is also worth noting that although the adjusted ACT score was higher in statin-users, there were no statistically significant improvements in the secondary endpoints (Table 2 ). This discrepancy may be due to the limitations of our sample size or other beneficial yet subtle statin effects captured by the ACT and not the singular measures of lung function or medication/inhaler use. The strength of the ACT score is that it has been validated against asthma specialist"s rating of symptom control, quality of life, and spirometric lung function25. The weakness of the ACT, however, is like any other scoring system or survey in clinical medicine: as a singular measure it cannot substitute for the entire clinical picture as assessed by the clinician at the bedside. This is especially true when discrepancies appear in the various indices of asthma control in the clinic. Despite this caveat, because of ACT"s predictive power (e.g. the MID as discussed above) in guiding clinical decisions, our findings taken in this light do point us in an important new direction."
2. Most of the severe asthmatics on statin therapy were taking statins for some co-morbid cardiovascular or hyperlipidemic conditions, so could the improvement in ACT score be somehow related to improvement in these co-morbid conditions and may not be associated with any improvement in asthma symptoms?
This is a very important point raised regarding potential confounders. Although the limits of an observational study design can never guarantee protection against such effects, we tried to control for confounders and co-morbid effects in our multivariate model. This allowed us to minimize the effects of any potential known confounders, including co-morbid cardiovascular disease and hyperlipidemia as mentioned above (we describe our approach in detail in the Online Supplement material under Statistical Analysis). This concern is best addressed by conducting randomized clinical trials to see if symptom control really is improved in severe asthmatics of similar comorbid status, including cardiovascular disease.
3. In the result section authors have talked about the effect of statins on only obese severe asthmatics, which is only a subgroup of severe asthmatics, but they have not mentioned the effect of statins on overall severe asthmatics included in the study.
We thank the reviewer for catching this subtle point and have made corrections to address this. We did not decide a priori to only study obese patients, but indeed studied all severe asthmatics in our clinic that met study inclusion criteria, as indicated in our Methods section. In our Results section it turns out that the population we studied was on average obese with a BMI > 30 (Table 1) . However, we do see where this may be confusing especially given the first sentence of the Discussion which states "We evaluated whether statin use in obese patients with severe asthma…". We have removed the word "obese" from this sentence to be more accurate. To be consistent, we have also removed the word "obese" from the last sentence of the 2nd paragraph in the Discussion, and from the first sentence of the Conclusions paragraph in the Discussion. Similar corrections have been made in the Article Summary to reflect these changes (see yellow highlighted text in the revised manuscript). The Results and conclusions drawn by us apply to all severe asthmatics in the cohort. However, we do point out that the obese asthmatic may be a subpopulation worthy of further study with respect to the statins. We hope this addresses the reviewer"s concern and clarifies our findings.
4. Study Cohort does not define obese severe asthmatics, the statistical model selection (backward selection procedure), where different variables associated with asthma has been taken into consideration, should be described in the main body of the paper.
We believe this comment relates to the one above it. Because our study was not designed to study only the obese severe asthmatic, but instead all subjects with severe asthma who qualified, we did not define the "obese severe asthmatic." Above we have clarified that the finding of obesity and all discussions surrounding it reflect the unexpected result that on average patients in this cohort were obese ( (2):406-414. We also added the following sentence in the Discussion page 17 to help clarify and contextualize the finding of obesity within our study: "Recent data suggest that obesity-associated severe asthma may be unique clinical phenotype requiring further study33." In terms of the details of the statistical model selection procedure, i.e. backward selection process, we prefer to keep this in the Online Supplement section given the length of text it takes to adequately explain it to readers. However, if the editors agree with the reviewer that this should be in the main text, we will be happy to include it.
Apart from these there are few minor comments 1. Page #13, line #31-33: "The lipophilic statins, which have the greatest lipid lowering potency" is incorrect as Rosuvastatin is the most potent statin, which is hydrophilic in nature. We thank the reviewer for this correction. We have edited that sentence to read as follows: "The lipophilic statins were used most commonly in our patients."
2. In the supplement material for statistical model development statistical significance has been observed at a p value≤0.1 instead of conventional 0.05 is there any specific reason for this?
For purposes of determining statistical significance the conventional p-value of 0.05 was used. However, model selection occurred in two phases: a univariate phase and a multiple regression phase. In the initial univariate phase, we used a decision limit of 0.1 to balance between the opposing needs of avoiding over-fitting and controlling for confounding variables. A confounding variable is, by definition, correlated with both the explanatory variable of interest and the endpoint. Hence, if there was even weak evidence of a relationship with statin, to be cautious, we included the variable for further testing in the multiple regression model, where it would it would only be retained if it had a pvalue less than 0.05. However, in the absence of even weak evidence (p-value > 0.1) we eliminated the variable in the initial phase as a possible confounder in order to avoid over-fitting (too many predictors for the endpoint of interest) and to retain sufficient power to test more probable confounders in the multiple regression phase. Statin use was included in all models until the final model in order to obtain a p-value once all possible confounders had been accounted for.
Reviewer: Dr Xin Yao First Affiliated Hospital of Nanjing Medical University. China
It is a retrospective, cross-sectional study focusing on the statins effect on severe asthma. The authors found out that statin-users had better asthma symptom control compared to non-users. The paper is well written and interesting.
Dr. Xin Yao"s comments regarding the study and manuscript are very helpful. We appreciate that he finds significant merit in the study. Two concerns were raised.
Major points: 1. The exclusion criteria included "COPD or emphysema … (Page 9, Line 44 to 50). Since the close relationship of asthma to the diseases above, did authors check the X-ray, CT-scan or some other tests to make sure of the exclusion?
The exclusion of COPD from the cohort is as described on page 8, under subheading Study Subjects. The diagnosis of COPD was based on that of the asthma pulmonary specialist based on clinical criteria such as PFT, spirometry, thoracic imaging, and history and physical examination. We did not review the chest x-ray or CT scans for each patient in the database to further confirm this diagnosis. Instead, we reviewed each chart closely to assure that a pulmonologist had made the diagnosis of asthma or COPD, and that any available PFTs in the chart were consistent with these diagnoses. Patients with asthma-COPD overlap syndrome were also excluded from the study, and we have corrected the text on page 8 to reflect this. Furthermore, we have added the following statement on pages 8-9 of the main text:
"The diagnosis of asthma and the exclusion of COPD (and other respiratory diseases) were based on clinical criteria as determined by the attending pulmonary asthma specialist, and as per above. These clinical parameters included but were not limited to the following: history and physical examination, PFT and/or spirometry, relevant laboratory tests, and thoracic imaging including chest x-ray and/or computed tomography (CT), where available."
2. The group of statin-user had significantly higher prevalence of CAD and hyperlipidemia than the non-user group. As we all know, coronary artery disease itself might cause chest tightness; and some of the patients may present with cardiac insufficiency, which were very likely to suffer from dyspnea, making it quite difficult for differential diagnosis just according to the symptoms. Furthermore, there were much more patients with CAD/ hyperlipidemia in statin group. Could it be possible that the better Adjusted Mean ACT score in statin-user group is mainly due to the statins effect on the coronary artery disease instead of asthma?
We understand and appreciate this concern, and it is similar to that of Professor Halayko"s above (major comment #2). This is, unfortunately, an unavoidable weakness in the study despite our best efforts to use multivariate statistical models to account for confounders. The confounding effects of CAD/hyperlipidemia cannot be fully accounted or controlled for using statistical methods alone because there were no observed subjects with CAD who were not on a statin. It is necessary to conduct a double-blind randomized controlled clinical trial to truly determine the effects of statins on severe asthma outcomes, whether positive or negative. We believe the physiology and biochemistry of the underlying mechanism, as well as the observed effect sizes, both the statistically significant and non-significant, indicate a need for further study.
